Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thean who wrote (18)	10/22/1996 5:50:00 PM
From: YOAV KEDAR	of 965

Hi, Though Reopro's sales are far from being exceptional the numbers are not bad. Eli lilly sold 38 million $ worth of the drug this quarter - meeting estimates I hold for the company. for the second quarter, Reopro's sales amounted to 30 million $. its difficult to say if and when Reopro will turn out to be a success for the company but patience is needed indeed. Reopro is an ongoing story and sales should be examined in a year to year basis. I agree - the company is not especially cheap right now but things could turn around fast if defenant results of clinical trials with Reopro come out (and there are more than few of them to the best of my knowledge). also, the TNF antibodies the company is developing for RA are interesting.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next